Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058599 | 0.87 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17411206 | 0.86 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CA1 | |
| SCHEMBL12012240 | 0.86 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CA1 | |
| SCHEMBL17391121 | 0.86 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CA1 | |
| SCHEMBL11888045 | 0.86 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CA1 | |
| SCHEMBL23669406 | 0.86 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2CA1 | |
| SCHEMBL22470033 | 0.86 | SMYD2 (0.44) | SMYD2CYP3A4HTTSMN1; SMN2MGAM | |
| SCHEMBL29624597 | 0.81 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2CA1 | |
| SCHEMBL31645153 | 0.81 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30411454 | 0.81 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
| CN-118488958-A | Compounds for degrading EGFR kinase | 百济神州有限公司 | 2024-08-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB3, ERBB2 | SMYD2 3591/4885CYP3A4 3237/4885HTT 4134/4885 |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | SMYD2 2579/4885CYP3A4 4752/4885HTT 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.